Anne Cross

Evaluation of CHIT1 and SERPINA3 as Candidate Cerebrospinal Fluid Biomarkers of Progressive Biology in Multiple Sclerosis (S33.003)

Amit Bar-Or, Jeffrey M. Gelfand, Chinaza Agbim, H.-Christian von Büdingen et autres

To quantitatively confirm associations between chitotriosidase-1 (CHIT1) or serpin family A member 3 (SERPINA3) and measures of multiple sclerosis (MS) progressive biology and quantitatively assess ocrelizumab treatment effect on cerebrospinal fluid (CSF) levels of these biomarkers.

us, ch (code pays fourni par la source)

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007)

Amit Bar‐Or, Heinz Wiendl, de Sèze, Jorge Correale et autres

Evaluate the effect of ofatumumab on serum immunoglobulin (Ig) levels ≤5 years during the core phase 3 ASCLEPIOS I/II (NCT02792218/NCT02792231) and on-going open-label ALITHIOS (NCT03650114) extension studies.

us, de, fr, ch, ca, it, in (code pays fourni par la source)

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300)

Amit Bar‐Or, de Sèze, Jorge Correale, Anne Cross et autres

To determine serum immunoglobulin (Ig) levels and investigate associations between IgG/IgM levels and infection risk in ofatumumab-treated patients.

us, fr, ch, de, in (code pays fourni par la source)

Blood Neurofilament Light Chain Levels and Association with Brain Volume Change in Patients with Primary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis Before and During Ocrelizumab Treatment (3926)

Xiaoming Jia, Ann Herman, Christopher Harp, Anne Cross et autres

To assess whether neurofilament light chain (NfL) levels measured before and during ocrelizumab treatment were associated with brain volume (BV) changes in patients with primary progressive multiple sclerosis (PPMS) or relapsing MS (RMS).

us, cl, ch (code pays fourni par la source)

Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420)

Amit Bar‐Or, Gian‐Andrea Thanei, Christopher Harp, Anne Cross et autres

To assess cross-sectional associations with neurofilament light (NfL) levels at baseline in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS).

us, ch, cl (code pays fourni par la source)

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

Nikolaos A. Patsopoulos, Sergio E. Baranzini, Adam Santaniello, Parisa Shoostari et autres

We analyzed genetic data of 47,429 multiple sclerosis (MS) and 68,374 control subjects and established a reference map of the genetic architecture of MS that includes 200 autosomal susceptibility variants outside the major histocompatibility complex (MHC), one chromosome X variant, and 32 …

us, gr, fr, de (code pays fourni par la source)

Project Tycho 2.0: a repository to improve the integration and reuse of data for global population health

Willem G. van Panhuis, Anne Cross, Donald S. Burke

Objective: In 2013, we released Project Tycho, an open-access database comprising 3.6 million counts of infectious disease cases and deaths reported for over a century by public health surveillance in the United States. Our objective is to describe how Project Tycho version …

us (code pays fourni par la source)

Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) (S24.002)

Amit Bar‐Or, Jeffrey A. Gelfand, Damian Fiore, Christopher Harp et autres

To provide interim analysis of the ocrelizumab cerebrospinal fluid (CSF) and blood biomarker study (OBOE, NCT02688985) in multiple sclerosis (MS).

us (code pays fourni par la source)

Jigsaw Research Communities: Coordinating Research and Service across Multiple Courses to Serve a Single Community Partner.

Anne Cross, Deborah A. Eckberg

Contagious Diseases in the United States from 1888 to the Present

Willem G. van Panhuis, John J. Grefenstette, Su Yon Jung, Nian Shong Chok et autres

Using data from digitized weekly surveillance reports of notifiable diseases for U.S. cities and states for 1888 through 2011, the authors derived a quantitative history of disease reduction in the United States, focusing particularly on the effects of vaccination programs.

us, cl (code pays fourni par la source)

Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B

Nancy Leung, Hie‐Won Hann, Jose D. Sollano, Judy Lao-Tan et autres

UNLABELLED: This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). Sixty-nine nucleoside-naïve CHB patients with baseline HBV DNA …

cn, tw, us, ph, id, ca (code pays fourni par la source)

998 ENTECAVIR (ETV) RESULTS IN HIGHER HBV DNA REDUCTION VERSUS ADEFOVIR (ADV) IN ANTIVIRAL-NAIVE HBEAG(+) ADULTS WITH HIGH HBVDNA: WEEK 96 RESULTS (E.A.R.L.Y. STUDY)

Nancy Leung, Cheng‐Yuan Peng, Jose D. Sollano, Laurentius A. Lesmana et autres

us, gb (code pays fourni par la source)